NEWS & LEGAL UPDATES · MEDICAL CANNABIS · JUNE 2026
UK and global medical cannabis news, legal updates and patient rights developments — curated for verified prescription holders. All stories sourced from primary and verified sources only.
UKMC Lounges is not a news organisation and does not produce original journalism. All articles link to their original verified sources. Nothing on this page constitutes legal, medical or financial advice.
LATEST STORIES
Source: National Police Chiefs' Council / leafie · 6 January 2026
The National Police Chiefs' Council approved the first-ever official guidance on medical cannabis for police officers in England and Wales on 6 January 2026 — instructing officers to treat verified prescription holders as “patients first, suspects second.” The guidance, authored by retired senior officer Richard List QPM, marks a landmark moment for the estimated 80,000–100,000 UK patients holding valid cannabis-based prescriptions. Officers are directed to verify prescriptions before taking enforcement action and to recognise prescribed cannabis as legally distinct from illegally obtained cannabis. Patients are strongly advised to carry their prescription letter or pharmacy delivery note at all times.
Read at leafie →
Source: LBC · November 2025
US venture capital firm Casa Verde Capital — co-founded by rapper Snoop Dogg — invested £4.5 million in Mamedica, the UK's leading medical cannabis clinic, in the largest fundraising in the UK medical cannabis sector to date. Mamedica reported 7,500 active patients at the time of the announcement, with projections to double by end of year. Fellow investors include former Premier League footballers Bobby Zamora and Mark Noble. Jon Robson, founder of Mamedica, told LBC that growing UK domestic supply could reduce costs, support the economy and reduce NHS waiting lists — noting that approximately 90% of UK medical cannabis products are currently imported.
Read at LBC →
Source: leafie · April 2026
The Welsh Liberal Democrats passed a motion at their Spring 2026 Conference calling for the protection of medical cannabis patients from discrimination — the first time a UK political party has adopted this as official policy. The motion, titled “Protecting Patients Prescribed Medical Cannabis and Other Essential Medicines from Discrimination in Wales,” builds on Salford City Council's 2023 precedent and calls on the party to use its presence in the Senedd to ensure public bodies, police forces and housing providers recognise cannabis-based medicinal products as legal prescribed medication. It challenges “no vaping” policies that force patients into outdoor smoking areas, arguing these breach the Equality Act 2010 by failing to provide reasonable adjustments for patients whose conditions meet the statutory definition of disability.
Read at leafie →
Source: LBC / Glass Pharms · November 2025
The UK medical cannabis market is approaching a £1 billion valuation and is expected to support 100,000 patients in 2026, according to industry analysis reported by LBC following a visit to Glass Pharms — one of the UK's largest Home Office-licensed cannabis cultivation facilities, located in Wiltshire. The facility uses robotics rather than human labour in cultivation to avoid contamination. An estimated 1.4 million people in the UK are still accessing cannabis illegally to manage health conditions, with the government noting that this carries a sentence of up to five years in prison. 90% of current UK medical cannabis products are imported from other countries.
Read at LBC →
Source: Releaf / PharmiWeb · 15 January 2026
Releaf, the UK's fastest-growing medical cannabis clinic with over 25,000 patients, launched Releaf Protect on 15 January 2026 — the UK's first dedicated legal guidance helpline for medical cannabis patients. The service provides 24/7 access to situation-specific legal guidance provided by Irwin Mitchell Solicitors, a leading UK law firm with extensive regulatory, employment and public law expertise. Available to eligible Releaf+ members, the service was developed in direct response to the gap between patients' legal rights and their lived experience of navigating police, workplace and public interactions. In the first four months of 2026, 114 patients used the helpline. Releaf does not receive the content of legal advice and does not influence guidance given.
Read at PharmiWeb →
Source: Cannabis Europa / Prohibition Partners · April 2026
Germany's medical cannabis market — now the largest in Europe — reached an estimated €670 million in annual value in 2025 and is projected to grow significantly through to 2029, according to Prohibition Partners. Over 100,000 patients are receiving cannabis under Germany's statutory health insurance (GKV) reimbursement system, with a significant additional cohort purchasing via private prescription. Germany's Cannabis Act (CanG), in force since April 2024, moved cannabis from the Narcotics Act to the Medicines Act, mandated GKV reimbursement for qualifying patients and established a Social Club framework. Prescription volumes tripled year-on-year following the reform. Germany remains structurally dependent on imports — domestic cultivation accounts for approximately 2.3 tonnes of an estimated total 212 tonnes dispensed annually.
Read at Cannabis Europa →
Source: GlobeNewswire · 14 May 2026
Europe's licensed cannabis industry is gaining significant momentum as more countries open medical cannabis programmes, expand patient access and create clearer licensing frameworks, according to a May 2026 GlobeNewswire analysis. Germany continues to lead following its 2024 Cannabis Act reforms, with the UK, Portugal, Italy, France, Switzerland and the Czech Republic also becoming major parts of the European cannabis economy. The European medical cannabis market is projected to reach €2–4 billion by 2028, driven by Germany's statutory reimbursement system, the UK's growing private prescribing sector and France's scaling medical cannabis pilot programme. Medical cannabis is now legal and accessible in 14+ European countries, though access conditions, qualifying conditions and reimbursement structures vary significantly between jurisdictions.
Read at GlobeNewswire →
Source: Cannabis Europa · April 2026
Medical cannabis is now legally accessible in more than 14 European countries, but access conditions, qualifying conditions and reimbursement structures vary dramatically between jurisdictions, according to Cannabis Europa's April 2026 country-by-country guide. Germany is the largest and most accessible market following the 2024 Cannabis Act. France's five-year medical cannabis pilot programme has been extended beyond March 2026. The UK's private prescribing sector continues to expand despite the absence of NHS commissioning. The Czech Republic legalised recreational use from 1 January 2026. No single EU framework governs medical cannabis — each country regulates independently under its own narcotics legislation, medicines law and clinical guidance. The European medical cannabis market is projected to reach €2–4 billion by 2028.
Read at Cannabis Europa →
Source: PatientsCann UK / Irwin Mitchell · 2026
Most conditions for which UK specialists prescribe cannabis-based medicinal products — including chronic pain, PTSD, epilepsy, multiple sclerosis and fibromyalgia — meet the statutory definition of disability under the Equality Act 2010. This means employers and public bodies have a legal duty to make reasonable adjustments for patients. PatientsCann UK's employment guidance, updated in 2026 and referencing a landmark Employment Appeal Tribunal ruling (Truman [2026] EAT 54), confirms that patients should disclose their prescription in writing before any workplace drug test and keep copies. A positive drug test linked to prescribed THC, without proper process, may expose an employer to an Equality Act claim. Patients are not generally required to disclose a cannabis prescription to an employer unless their role involves safety-critical activities.
Read at PatientsCann UK →
Source: Business of Cannabis · January 2026
The National Police Chiefs' Council guidance approved on 6 January 2026 represents the first official framework for how officers in England and Wales should approach interactions with medical cannabis patients. The guidance introduces the concept of CAN Cards — patient identification cards carrying prescription details — and sets out officer protocols for verifying prescriptions before any enforcement action. Business of Cannabis reports that the guidance was undermined within days by national press coverage framing legitimate prescriptions as a “loophole,” illustrating the ongoing gap between patient legal rights and public understanding. The guidance explicitly recognises that prescribed cannabis is legally distinct from illegally obtained cannabis and that a “patients first, suspects second” approach reflects good policing practice.
Read at Business of Cannabis →
Source: leafie / Liberal Democrats · April 2026
The Welsh Liberal Democrats' Spring 2026 Conference motion explicitly challenges blanket “no vaping” and “no smoking” policies at public venues and housing, arguing they may breach the Equality Act 2010 by failing to provide reasonable adjustments for patients with qualifying disabilities. The motion calls on the Equality Act's Section 20 reasonable adjustment duty to be applied consistently to medical cannabis patients — noting that forcing prescription holders into outdoor smoking areas alongside tobacco smokers exposes them to carcinogenic second-hand smoke and constitutes potentially discriminatory treatment. The motion builds on Salford City Council's November 2023 precedent, which was the first local authority to establish safe indoor spaces for prescription holders under the Equality Act framework, and on Flintshire County Council's adoption of a similar motion in April 2025.
Read at leafie →
Source: PatientsCann UK · 2026
PatientsCann UK's housing guidance, supported by Freedom of Information responses from the Department of Health and Social Care and the Home Office, confirms that there is no legislation specifically prohibiting dry herb vaporising in private or public indoor spaces. Landlords and housing associations threatening tenants with eviction for using legally prescribed cannabis-based medicinal products may be in breach of the Equality Act 2010 and the Human Rights Act. Article 8 of the Human Rights Act protects the right to respect for private and family life and the home — a landlord discriminating against a tenant's lawful medical treatment in their own home may engage both Article 8 and Article 14. PatientsCann UK provides template letters for patients facing challenges from landlords and links to the DHSC and Home Office FOI responses as supporting documentation.
Read at PatientsCann UK →
LEGAL RESOURCES · FROM LAW FIRMS ONLY
The following legal resources are from verified UK law firms and official legal organisations only. UKMC Lounges has no commercial relationship with any of these firms. Nothing below constitutes legal advice — for advice specific to your situation, consult a qualified solicitor.
LAW FIRM · IRWIN MITCHELL
Irwin Mitchell is the law firm powering the Releaf Protect legal helpline — the UK's first dedicated legal support service for medical cannabis patients. Irwin Mitchell has extensive experience in regulatory, employment and public law. Their guidance covers patient rights in workplaces, public spaces and police interactions. Available to eligible Releaf+ patients from January 2026.
Visit Irwin Mitchell →SPECIALIST SOLICITOR · EQUALITY & DISABILITY
PatientsCann UK maintains a verified directory of solicitors and legal organisations specialising in medical cannabis law in the UK. Listed firms include Ringrose Law (Equality and Disability Rights — Head of Discrimination and Equality Department Carrie Wootten) and Fieldfisher LLP (criminal investigations, regulation, compliance, public and administrative law, and licensing matters related to medical cannabis).
Visit PatientsCann Legal Directory →LAW FIRM · FIELDFISHER LLP
Fieldfisher LLP is a leading UK law firm with a partner specialising in criminal investigations and prosecutions, regulation and compliance, public and administrative law — including licensing matters specific to medical cannabis. Listed by PatientsCann UK as a verified specialist for patients requiring legal support on cannabis-related regulatory and compliance matters.
Visit Fieldfisher LLP →OFFICIAL GOVERNMENT RESOURCE
The House of Commons Library maintains an authoritative, regularly updated research briefing on the medical use of cannabis in the UK — covering the legal framework, the rescheduling history, NHS and private prescribing, licensed products and the clinical trial landscape. Last updated June 2026. The most authoritative single-source summary of UK medical cannabis law available from a government source.
Read at House of Commons Library →All news stories on this page link to their original sources. UKMC Lounges does not produce original journalism and is not a news organisation. All stories were verified from primary and institutional sources at the time of publication. Story accuracy is the responsibility of the original publisher. UKMC Lounges has no commercial relationship with any publication, law firm or organisation linked on this page. Nothing on this page constitutes medical, legal or financial advice. For medical advice, consult a GMC-registered specialist doctor. For legal advice, consult a qualified solicitor.